Stroke Prevention in Atrial Fibrillation

Atrial Fibrillation affects approximately 2.3 million people in the United States and is the most common rhythm disorder among U.S. patients hospitalized with a primary diagnosis of an cardiac arrhythmia. The median age of Atrial Fibrillation patients is 75 years; 84% are older than 65 years. Pooled data from studies of chronic Atrial Fibrillation in North America, Britain, and Iceland suggest a prevalence of 0.5% to 1% in the general population. (more…)

Supraventricular & Ventricular Tachyarrhythmia: Therapy and Drugs Management

Supraventricular Tachyarrhythmia

The principles of drug and non-drug management of supraventricular tachyarrhythmia (SVT) are similar to those outlined for stroke Atrial Fibrillation. However, for most supraventricular tachyarrhythmia, the arrhythmogenic substrate is isolated and well defined. AV nodal reentrant tachycardia (localized to the region of AVN) and atrioventricular reentrant tachycardia (with use of an accessory pathway) are the two most common types of supraventricular tachyarrhythmia. Atrial tachycardia can be reentrant or non-reentrant in mechanism, can be right or left atrial in origin, and can occur more frequently in the elderly population than in younger patients. (more…)